---
created: 2025-07-21 11:25
updated: 2025-08-02 15:52
---

##### 114-2(1) +
```Question
è‹¥ä¸€è—¥ç‰©æ˜¯æŸå—é«”ï¼ˆreceptorï¼‰çš„éç«¶çˆ­æ€§æ‹®æŠ—åŠ‘ï¼ˆnoncompetitive antagonistï¼‰ï¼Œå‰‡æœ‰é—œè©²è—¥ç‰©è—¥ç†æ€§è³ªä¹‹æ•˜è¿°ï¼Œä¸‹åˆ—ä½•è€…æœ€é©ç•¶ï¼Ÿ
```
(A) æ‡‰æœƒèˆ‡è©²å—é«”ä½œç”¨åŠ‘ï¼ˆagonistï¼‰ç«¶çˆ­ç›¸åŒçš„çµåˆä½é»ï¼Œå¯ä½¿è©²å—é«”ä½œç”¨åŠ‘ï¼ˆagonistï¼‰çš„EC50æ”¹è®Š
(B) æ‡‰æœƒèˆ‡è©²å—é«”é€²è¡Œä¸å¯é€†çš„å…±åƒ¹éµçµåˆï¼ˆcovalent bindingï¼‰ï¼Œå¯ä½¿è©²å—é«”ä½œç”¨åŠ‘ï¼ˆagonistï¼‰çš„EC50æ”¹è®Š
(C) è‹¥è©²è—¥ç‰©å±¬ä¸å¯é€†æ‹®æŠ—åŠ‘ï¼Œç•¶éé‡ä¸­æ¯’æ™‚ï¼Œå¯é€éå¢åŠ è©²å—é«”ä½œç”¨åŠ‘ï¼ˆagonistï¼‰çš„åŠ‘é‡è€Œè§£æ¯’
(D) è‹¥è©²è—¥ç‰©å±¬ä¸å¯é€†æ‹®æŠ—åŠ‘ï¼Œå…¶ä½œç”¨æœŸé–“ï¼ˆduration of actionï¼‰ä¸»è¦å–æ±ºè©²å—é«”çš„ä»£è¬é€Ÿç‡ï¼ˆturnover rateï¼‰
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šD
èªªæ˜ï¼šéç«¶çˆ­æ€§æ‹®æŠ—åŠ‘å¸¸è—‰ç”±ä¸å¯é€†çµåˆæŠ‘åˆ¶å—é«”ï¼Œå…¶è—¥æ•ˆé•·çŸ­èˆ‡å—é«”å†ç”Ÿæœ‰é—œã€‚
???

##### 114-2(2) +
```Question
ä¸‹åˆ—ä½•è€…ç‚ºç´°èŒå°aminoglycosidesç”¢ç”ŸæŠ—è—¥æ€§ï¼ˆresistanceï¼‰çš„ä¸»è¦æ©Ÿè½‰ï¼Ÿ
```
(A) å¢åŠ è—¥ç‰©çš„æ’å‡º
(B) æ”¹è®Šè—¥ç‰©çš„çµåˆä½ç½®
(C) èª˜ç™¼è—¥ç‰©ä»£è¬é…µç´ çš„ç”Ÿæˆ
(D) æ”¹è®Šè‘‰é…¸çš„ç”Ÿåˆæˆè·¯å¾‘
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šA/B
èªªæ˜ï¼šaminoglycosides æŠ—è—¥æ€§å¤šä¾†è‡ªç´°èŒç”¢ç”Ÿ modifying enzymesï¼Œå¦‚acetyltransferaseç­‰ï¼Œç ´å£è—¥ç‰©çµæ§‹ã€‚
???

##### 114-2(3) +
```Question
ä¸‹åˆ—ä½•ç¨®è—¥ç‰©æœ€é©åˆç”¨æ–¼æ²»ç™‚ç¶ è†¿æ¡¿èŒï¼ˆPseudomonas aeruginosaï¼‰æ‰€å¼•èµ·çš„æ„ŸæŸ“ï¼Ÿ
```
(A) cefamandole
(B) teicoplanin
(C) linezolid
(D) piperacillin
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šD
èªªæ˜ï¼špiperacillin ç‚ºæŠ—ç¶ è†¿æ¡¿èŒçš„å»£æ•ˆ penicillin é¡æŠ—ç”Ÿç´ ã€‚
???

##### 114-2(4) +
```Question
Leucovorinå¸¸è¢«ç”¨æ–¼æ”¹å–„ä¸‹åˆ—ä½•ç¨®æŠ—ç™Œè—¥ç‰©å°æ–¼æ­£å¸¸çµ„ç¹”ç´°èƒä¹‹æ¯’æ€§ï¼Ÿ
```
(A) gemcitabine
(B) methotrexate
(C) 6-mercaptopurine
(D) bleomycin
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB
èªªæ˜ï¼šLeucovorin å¯æ¸›å°‘ methotrexate å°æ­£å¸¸ç´°èƒçš„è‘‰é…¸æ‹®æŠ—æ¯’æ€§ï¼Œä½œç‚ºã€Œfolinic acid rescueã€ã€‚
???

##### 114-2(5) +
```Question
ä¸‹åˆ—æŠ—ç™Œè—¥ç‰©èˆ‡å…¶å¯èƒ½ç”¢ç”Ÿå‰¯ä½œç”¨ä¹‹é…å°ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) cyclophosphamideï¼šhemorrhagic cystitis
(B) cisplatinï¼šhypotension
(C) bleomycinï¼špulmonary fibrosis
(D) doxorubicinï¼šcardiotoxicity
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB æ‡‰è©²æ˜¯é«˜è¡€å£“
èªªæ˜ï¼šcisplatin çš„å¸¸è¦‹å‰¯ä½œç”¨ç‚ºè…æ¯’æ€§èˆ‡è€³æ¯’æ€§ï¼Œhypotension ä¸¦éå¸¸è¦‹å‰¯ä½œç”¨ã€‚
???

##### 114-2(6) +
```Question
ç™Œç—‡å…ç–«ç™‚æ³•å¯é€éä½¿ç”¨å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ï¼ˆimmune checkpoint inhibitorï¼‰æŠ‘åˆ¶Tç´°èƒä¸Šä¹‹ cytotoxic T-lymphocyte-associated antigen 4ï¼ˆCTLA-4ï¼‰æˆ–æ˜¯é˜»æ–·Tç´°èƒä¸Šä¹‹ programmed death receptor-1ï¼ˆPD-1ï¼‰å’Œè…«ç˜¤ç´°èƒä¸Šä¹‹PD-ligand-1ï¼ˆPD-L1ï¼‰çµåˆï¼Œé€²è€Œå¢å¼·å…ç–«ç´°èƒæ¯’æ®ºè…«ç˜¤ç´°èƒä¹‹ä½œç”¨ã€‚ä¸‹åˆ—æŠ—ç™Œè—¥ç‰©ä¸­ï¼Œä½•è€…ä¸å±¬æ–¼å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ï¼Ÿ
```
(A) ipilimumab
(B) rituximab
(C) pembrolizumab
(D) atezolizumab
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB
èªªæ˜ï¼šrituximab æ˜¯æŠ—CD20å–®æ ªæŠ—é«”ï¼Œç”¨æ–¼Bç´°èƒæ·‹å·´ç˜¤ï¼Œä¸å±¬æ–¼å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ã€‚
???

##### 114-2(7) +
```Question
ä¸‹åˆ—æ•˜è¿°ä½•è€…æ­£ç¢ºï¼Ÿ
```
(A) doxycycline, minocyclineå¯ç”¨æ–¼tetracyclineæŠ—è—¥æ€§èŒæ ªï¼Œæ˜¯å› ç‚ºèˆ‡ç´°èŒæ ¸ç³–é«”ä¹‹çµåˆåŠ›æ›´å¼·
(B) clindamycin, chloramphenicol, linezolidçš†æœƒæŠ‘åˆ¶ç´°èŒçš„50Sæ ¸ç³–é«”åŠŸèƒ½
(C) tetracycline, doxycyclineéƒ½å¿…é ˆç©ºè…¹ä½¿ç”¨
(D) tigecyclineåœ¨è¡€æ¸…ä¸­çš„åŠè¡°æœŸæ¯”tetracyclineçŸ­
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šA (ä¸€æ™‚è…¦éœ§ï¼Œå°±æ˜¯ä¸ç†Ÿ)
èªªæ˜ï¼šé¸é … B çš†ä½œç”¨æ–¼50Sæ ¸ç³–é«”ï¼›è€Œ A çš„è€è—¥æ€§å¸¸å› efflux pumpï¼ŒéçµåˆåŠ›ï¼›CéŒ¯å› doxycycline å¯èˆ‡é£Ÿç‰©ä½µç”¨ï¼›DéŒ¯ï¼Œtigecycline åŠè¡°æœŸè¼ƒé•·ã€‚
???

##### 114-2(8) +
```Question
æœ‰é—œæŠ—è¡€å°æ¿å‡é›†è—¥ç‰©ä¹‹æ©Ÿè½‰ï¼Œä¸‹åˆ—æ•˜è¿°ä½•è€…æ­£ç¢ºï¼Ÿ
```
(A) vorapaxaræŠ‘åˆ¶è¡€å°æ¿ä¸Šprotease-activated receptor 1ï¼ˆPAR-1ï¼‰
(B) ticagreloræŠ‘åˆ¶è¡€å°æ¿ä¸Šglycoprotein IIb/IIIa receptor
(C) clopidogrelæŠ‘åˆ¶è¡€å°æ¿phosphodiesteraseï¼ˆPDEï¼‰
(D) tirofibanæŠ‘åˆ¶è¡€å°æ¿thromboxane A2çš„ç”Ÿæˆ
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼švorapaxar æ˜¯PAR-1æ‹®æŠ—åŠ‘ï¼ŒæŠ‘åˆ¶å‡è¡€é…¶ï¼ˆthrombinï¼‰ä»‹å°çš„è¡€å°æ¿æ´»åŒ–ã€‚
???

##### 114-2(9) +
```Question
æœ‰é—œéµåŠ‘æ²»ç™‚è²§è¡€ä¹‹æ•˜è¿°ï¼Œä¸‹åˆ—ä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) éµåŠ‘å¯ç”¨æ–¼æ²»ç™‚ä½è¡€ç´ å°ç´°èƒå‹è²§è¡€ï¼ˆmicrocytic hypochromic anemiaï¼‰
(B) å£æœéµåŠ‘ä½¿ç”¨æ™‚æœƒå¹²æ“¾è…¸èƒƒé“å‡ºè¡€çš„åˆ¤è®€
(C) æ³¨å°„deferoxamineå¯ä»¥æ²»ç™‚æ€¥æ€§éµä¸­æ¯’
(D) éµåŠ‘æ²»ç™‚è²§è¡€çš„ä¸»è¦è—¥ç†æ©Ÿè½‰ç‚ºå¹«åŠ©ç´…è¡€çƒä¸­è‘‰é…¸æ‰€åƒèˆ‡ä¹‹å–®ç¢³å¾ªç’°
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šD
èªªæ˜ï¼šéµåŠ‘ä¸»è¦æ˜¯è£œå……éµè³ªåƒèˆ‡è¡€ç´…ç´ ç”Ÿæˆï¼Œè‘‰é…¸åƒèˆ‡çš„æ˜¯ DNA åˆæˆï¼Œä¸æ˜¯éµåŠ‘ä½œç”¨æ©Ÿè½‰ã€‚
???

##### 114-2(10)
```Question
é—œæ–¼recombinant human granulocyte colony-stimulating factorï¼ˆrHuG-CSFï¼‰ä¹‹è‡¨åºŠæ‡‰ç”¨ï¼Œä¸‹åˆ—ä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) å¯ç”¨æ–¼æ²»ç™‚ç™Œç—‡åŒ–ç™‚æ‰€å°è‡´å—œä¸­æ€§ç™½è¡€çƒç¼ºä¹ç—‡ï¼ˆchemotherapy-induced neutropeniaï¼‰
(B) å¯ç”¨æ–¼è‡ªé«”å¹¹ç´°èƒç§»æ¤ï¼ˆautologous stem cell transplantationï¼‰
(C) èˆ‡plerixaforä½µç”¨ä»¥æ²»ç™‚å¤šç™¼æ€§éª¨é«“ç˜¤ï¼ˆmultiple myelomaï¼‰
(D) å¯å–®ç¨ç”¨æ–¼æ²»ç™‚å…¨è¡€çƒç´°èƒç¼ºä¹ç—‡ï¼ˆpancytopeniaï¼‰
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šBC
èªªæ˜ï¼šrHuG-CSF åƒ…åˆºæ¿€å—œä¸­æ€§çƒç”Ÿæˆï¼Œå°å…¨è¡€çƒç¼ºä¹ç—‡ç„¡æ•ˆï¼Œé ˆåˆä½µå…¶ä»–åˆºæ¿€å› å­ã€‚
???

##### 114-2(11) +
```Question
ä¸‹åˆ—æ²»ç™‚ç”²ç‹€è…ºé¢¨æš´ï¼ˆthyroid stormï¼‰è—¥ç‰©ä¸­ï¼Œä½•è€…å¯æŠ‘åˆ¶thyroid peroxidaseè€ŒæŠ‘åˆ¶ç”²ç‹€è…ºç´ ç”Ÿåˆæˆï¼Ÿ
```
(A) propranolol
(B) propylthiouracil
(C) iodides
(D) glucocorticoids
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šC (ç´”ç²¹å¹»è¦º)é€™é¡Œç®—æ˜¯è€ƒå¤
èªªæ˜ï¼špropylthiouracilï¼ˆPTUï¼‰å¯æŠ‘åˆ¶thyroid peroxidaseï¼Œé˜»æ–·ç¢˜åŒ–èˆ‡å¶åˆåæ‡‰ï¼Œæ¸›å°‘T3/T4åˆæˆã€‚
???

##### 114-2(12) +
```Question
ä¸‹åˆ—ä½•è€…ç‚ºå£æœé™è¡€ç³–è—¥ç‰©ï¼Œå¯ä½œç”¨æ–¼sulfonylureaå—é«”ï¼Œè€Œå¢åŠ insuliné‡‹æ”¾ï¼Ÿ
```
(A) glyburide
(B) metformin
(C) liraglutide
(D) rosiglitazone
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šglyburide ç‚ºç¬¬äºŒä»£sulfonylureaé¡ï¼Œåˆºæ¿€èƒ°å³¶Î²ç´°èƒé‡‹æ”¾èƒ°å³¶ç´ ã€‚
???

##### 114-2(13) +
```Question
ä¸‹åˆ—ç³–å°¿ç—…çš„æ²»ç™‚è—¥ç‰©ä¸­ï¼Œä½•è€…ç‚ºglucagon-like polypeptide-1å—é«”è‡´æ•ˆåŠ‘ï¼Ÿ
```
(A) glipizide
(B) dapagliflozin
(C) semaglutide
(D) miglitol
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šC
èªªæ˜ï¼šsemaglutide ç‚ºGLP-1 receptor agonistï¼Œå¯ä¿ƒé€²èƒ°å³¶ç´ åˆ†æ³Œä¸¦å»¶ç·©èƒƒæ’ç©ºã€‚
???

##### 114-2(14) +
```Question
ä¸‹åˆ—bisphosphonatesé¡è—¥ç‰©ä¸­ï¼Œä½•è€…åªéœ€è¦æ¯å¹´éœè„ˆæ³¨å°„5 mgä¸€æ¬¡ï¼Œå³å¯æœ‰æ•ˆæ²»ç™‚éª¨è³ªç–é¬†ç—‡ï¼Ÿ
```
(A) alendronate
(B) risedronate
(C) zoledronate
(D) ibandronate
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šC
èªªæ˜ï¼šzoledronate æ¯å¹´æ³¨å°„ä¸€æ¬¡å³å¯æœ‰æ•ˆæ²»ç™‚éª¨è³ªç–é¬†ï¼Œæ˜¯ä½œç”¨åŠ›æœ€å¼·çš„bisphosphonateä¹‹ä¸€ã€‚
???

##### 114-2(15) +
```Question
æŠ—å¿ƒå¾‹ä¸æ•´è—¥ç‰©ä¸­ï¼Œéˆ‰é›¢å­é€šé“é˜»æ–·åŠ‘å¯æŠ‘åˆ¶å¿ƒè‚Œå‹•ä½œé›»ä½é›¶æœŸå»æ¥µåŒ–é€Ÿåº¦ï¼Œå…¶æŠ‘åˆ¶ç¨‹åº¦ç”±å¤§åˆ°å°æ’åºï¼Œä½•è€…æ­£ç¢ºï¼Ÿ
```
(A) flecainideï¼quinidineï¼lidocaine
(B) lidocaineï¼propafenoneï¼quinidine
(C) quinidineï¼mexiletineï¼propafenone
(D) mexiletineï¼quinidineï¼flecainide
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šClass I éˆ‰é€šé“é˜»æ–·åŠ‘ä¸­ï¼ŒIaï¼ˆå¦‚quinidineï¼‰ä½œç”¨ä¸­ç­‰ï¼ŒIbï¼ˆå¦‚lidocaineï¼‰ä½œç”¨æœ€å¼±ï¼ŒIcï¼ˆå¦‚flecainideï¼‰ä½œç”¨æœ€å¼·ã€‚
???

##### 114-2(16) -
```Question
ä¸‹åˆ—æŠ—å¿ƒå¾‹ä¸æ•´è—¥ç‰©ä¸­ï¼Œå¯èƒ½å°è‡´å¿ƒé›»åœ–QT intervalå»¶é•·ï¼Œå¼•èµ·å¿ƒå¾‹ä¸æ•´å‰¯ä½œç”¨ä¹‹æ©Ÿåˆ¶ç‚ºä½•ï¼Ÿ
```
(A) propafenoneï¼ŒæŠ‘åˆ¶éˆ‰é›¢å­é€šé“ï¼Œä½†æœƒå°è‡´INa slow inactivationï¼Œç”¢ç”Ÿdelayed afterdepolarizations
(B) sotalolï¼Œæ‹®æŠ—Î²-adrenergic receptorï¼Œç”¢ç”Ÿdelayed afterdepolarizations
(C) amiodaroneï¼ŒæŠ‘åˆ¶é‰€é›¢å­é€šé“ï¼Œå°¤å…¶æ˜¯IKrï¼Œç”¢ç”Ÿearly afterdepolarizations
(D) adenosineï¼Œæ‹®æŠ—A1 receptorï¼ŒæŠ‘åˆ¶é‰€é›¢å­é€šé“ï¼Œç”¢ç”Ÿearly afterdepolarizations
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šB
èªªæ˜ï¼šamiodarone ç‚ºclass IIIæŠ—å¿ƒå¾‹ä¸æ•´è—¥ï¼Œå»¶é•·å‹•ä½œé›»ä½ï¼ŒQTå»¶é•·å¯èƒ½å°è‡´early afterdepolarizationsã€‚
???

##### 114-2(17) -
```Question
é é˜²æ²»ç™‚ä¸ç©©å®šå‹å¿ƒçµç—›ï¼ˆunstable anginaï¼‰è¡€æ “ç™¼ç”Ÿä¹‹è—¥ç‰©åŠä½œç”¨æ©Ÿåˆ¶ï¼Œä¸‹åˆ—ä½•è€…æ­£ç¢ºï¼Ÿ
```
(A) æŠ—è¡€å°æ¿è—¥dipyridamoleâ€”æŠ‘åˆ¶phosphodiesterase
(B) æŠ—è¡€å°æ¿è—¥abciximabâ€”æŠ‘åˆ¶glycoprotein IIb/IIIa
(C) éå£æœæŠ—å‡åŠ‘dabigatranâ€”æŠ‘åˆ¶thrombinåŠXaå› å­
(D) éå£æœæŠ—å‡åŠ‘rivaroxabanâ€”æŠ‘åˆ¶Xaå› å­
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šA (æ˜¯å› ç‚ºAæè¿°ä¸å¤ å®Œæ•´å—?)çµæœæ˜¯å› ç‚ºæ²»ç™‚å­¸
èªªæ˜ï¼šabciximab ç‚ºå–®æ ªæŠ—é«”ï¼ŒæŠ‘åˆ¶GP IIb/IIIaå—é«”ï¼Œé˜»æ­¢è¡€å°æ¿èšé›†ã€‚
???

##### 114-2(18) +
```Question
ä¸‹åˆ—åˆ©å°¿åŠ‘ä¸­ï¼Œä½•è€…æœ€ä¸æ˜“å¼•ç™¼ä½è¡€é‰€å‰¯ä½œç”¨ï¼Ÿ
```
(A) chlorothiazide
(B) furosemide
(C) acetazolamide
(D) eplerenone
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šD
èªªæ˜ï¼šeplerenone ç‚ºä¿é‰€å‹åˆ©å°¿åŠ‘ï¼ˆAldosterone antagonistï¼‰ï¼Œæœ€ä¸æ˜“å°è‡´ä½è¡€é‰€ã€‚
???

##### 114-2(19) +
```Question
é—œæ–¼acetazolamideä¹‹è—¥ç†ä½œç”¨åŠå‰¯ä½œç”¨æ•˜è¿°ï¼Œä½•è€…æ­£ç¢ºï¼Ÿ
```
(A) æŠ‘åˆ¶proximal convoluted tubuleä¹‹carbonic anhydrase
(B) æŠ‘åˆ¶distal convoluted tubuleä¹‹HCO3â» reabsorption
(C) é•·æœŸæ²»ç™‚éœ€è£œå……HCO3â»ï¼Œä½†æ˜“æ–¼è…è‡Ÿå½¢æˆcalcium chloride crystal
(D) èƒ½å¹³è¡¡å‘¼å¸æ€§é…¸ä¸­æ¯’ï¼Œå¯ç”¨æ–¼é é˜²é«˜å±±ç—‡
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šacetazolamide ç‚ºcarbonic anhydrase inhibitorï¼Œä½œç”¨æ–¼è¿‘æ›²å°ç®¡ï¼ŒæŠ‘åˆ¶Hâºèˆ‡HCO3â»çš„äº¤æ›ã€‚
???

##### 114-2(20) +
```Question
Angiotensin converting enzymeæŠ‘åˆ¶åŠ‘ç¦ç”¨æ–¼å¦Šå¨ ç¬¬äºŒæœŸåŠç¬¬ä¸‰æœŸä¹‹é«˜è¡€å£“ç—…äººï¼Œä¸‹åˆ—ä½•è€…ä¸¦éå…¶ä¸»è¦åŸå› ï¼Ÿ
```
(A) fetal hypotension
(B) hypokalemia
(C) renal failure
(D) fetal malformations
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB (ä¸ç¢ºå®š)
èªªæ˜ï¼šACEiå¸¸å°è‡´é«˜è¡€é‰€ï¼ˆhyperkalemiaï¼‰ï¼Œéä½è¡€é‰€ï¼Œä¸”å°èƒå…’å…·è‡´ç•¸æ€§èˆ‡è…æ¯’æ€§ã€‚
???

##### 114-2(21) +
```Question
ä¸‹åˆ—ä½•è€…æ˜¯Î±2 adrenergic agonistï¼Œä¸»è¦ç”¨é€”ä½œç‚ºä¸­æ¨æ€§è‚Œè‚‰é¬†å¼›åŠ‘ï¼ˆcentrally acting muscle relaxantï¼‰ï¼Ÿ
```
(A) tizanidine
(B) formoterol
(C) phenylephrine
(D) prazosin
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šB (æŠŠ Clonidine è¨˜æ†¶æˆÎ±1)
èªªæ˜ï¼štizanidine ç‚ºÎ±2è‡´æ•ˆåŠ‘ï¼Œå…·ä¸­æ¨æŠ‘åˆ¶ä½œç”¨ï¼Œå¯ç”¨æ–¼æ²»ç™‚è‚Œè‚‰ç—™æ”£ã€‚
???

##### 114-2(22)
```Question
ä¸‹åˆ—ä½•è€…æ˜¯é–“æ¥ä½œç”¨å‹æ“¬äº¤æ„Ÿç¥ç¶“ä½œç”¨åŠ‘ï¼ˆindirect-acting sympathomimeticsï¼‰modafinilä¹‹è‡¨åºŠç”¨é€”ï¼Ÿ
```
(A) æ°£å–˜ï¼ˆasthmaï¼‰
(B) çŒç¡ç—‡ï¼ˆnarcolepsyï¼‰
(C) ä¼‘å…‹ï¼ˆshockï¼‰
(D) åé ­ç—›ï¼ˆmigraineï¼‰
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼š
èªªæ˜ï¼šmodafinil å¯ä¿ƒé€²ä¸­æ¨ç¥ç¶“æ¸…é†’ï¼Œå¸¸ç”¨æ–¼æ²»ç™‚çŒç¡ç—‡èˆ‡ç¡çœ å‘¼å¸ä¸­æ­¢ç—‡ã€‚
???

##### 114-2(23) +
```Question
ä¸‹åˆ—ä½•è€…ç‚ºÎ²1 adrenergic agonistï¼Œå…·æœ‰å¼·å¿ƒä½œç”¨ï¼Œå¯ç”¨æ–¼æ²»ç™‚å¿ƒå› æ€§ä¼‘å…‹ï¼ˆcardiogenic shockï¼‰ç—…äººï¼Ÿ
```
(A) dobutamine
(B) isoproterenol
(C) metaproterenol
(D) metoprolol
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šdobutamine é¸æ“‡æ€§æ´»åŒ– Î²1 å—é«”ï¼Œå¢åŠ å¿ƒè¼¸å‡ºé‡ï¼Œå¸¸ç”¨æ–¼æ€¥æ€§å¿ƒè¡°ç«­èˆ‡å¿ƒå› æ€§ä¼‘å…‹ã€‚
???

##### 114-2(24) - AIç­”éŒ¯ +
```Question
ä¸‹åˆ—è—¥ç‰©ä¸­ï¼Œä½•è€…å±¬æ–¼é¸æ“‡æ€§Î²1 adrenergic receptor blockerï¼Œä¸”ä¸å…·å±€éƒ¨éº»é†‰ä½œç”¨ï¼Ÿ
```
(A) nebivolol
(B) nadolol
(C) propranolol
(D) sotalol
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šB (åŸæœ¬é¸å°ï¼Œè¦èƒŒå¥½å£è¨£)
èªªæ˜ï¼šsotalol ç‚ºÎ²1é¸æ“‡æ€§é˜»æ–·åŠ‘ï¼Œä¸¦å…·class IIIæŠ—å¿ƒå¾‹ä¸æ•´ä½œç”¨ï¼Œä¸å…·membrane-stabilizingï¼ˆå±€éº»ï¼‰æ•ˆæœã€‚
???

##### 114-2(25) +
```Question
ä¸‹åˆ—ä½•è€…å±¬æ–¼ä¹™é†¯è†½é¹¼é‡‹æ”¾èª¿æ§åŠ‘ï¼ˆacetylcholine release modulatorï¼‰ï¼Œå¯ç”¨æ–¼æ²»ç™‚è—ä¼¯ï¼ä¼Šé “è‚Œç„¡åŠ›ç—‡å€™ç¾¤ï¼ˆLambert-Eaton myasthenic syndromeï¼‰ï¼Ÿ
```
(A) amifampridine
(B) atropine
(C) echothiophate
(D) bethanechol
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šamifampridine ç‚ºKâºé€šé“é˜»æ–·åŠ‘ï¼Œå¯ä¿ƒé€²ä¹™é†¯è†½é¹¼é‡‹æ”¾ï¼Œç”¨æ–¼æ²»ç™‚LEMSã€‚
???

##### 114-2(26) +
```Question
ä¸‹åˆ—æ°£å–˜ç”¨è—¥ä¸­ï¼Œä½•è€…é›–æ²’æœ‰ç›´æ¥æ”¯æ°£ç®¡æ“´å¼µä½œç”¨ï¼Œä½†æœ‰ç©©å®šè‚¥å¤§ç´°èƒï¼ˆmast cell stabilizerï¼‰ä¹‹ä½œç”¨ï¼Ÿ
```
(A) ipratropium
(B) albuterol
(C) zileuton
(D) nedocromil
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šD
èªªæ˜ï¼šnedocromil ç‚ºmast cell stabilizerï¼Œå¯é é˜²è‚¥å¤§ç´°èƒé‡‹æ”¾ç™¼ç‚ç‰©è³ªï¼Œä½†ç„¡æ”¯æ°£ç®¡æ“´å¼µæ•ˆæœã€‚
???

##### 114-2(27)
```Question
ä¸‹åˆ—ä½•è€…ä¸æ˜¯metoclopramideå¯èƒ½å¼•èµ·çš„ä¸è‰¯åæ‡‰ï¼Ÿ
```
(A) ä¾¿ç§˜
(B) ä¹³æ¼ã€ç”·æ€§å¥³ä¹³ç—‡å’Œå‹ƒèµ·åŠŸèƒ½éšœç¤™
(C) éŒé«”å¤–ç—‡å€™ç¾¤ï¼ˆextrapyramidal adverse reactionsï¼‰
(D) å›°å€¦å’Œç„¦æ…®
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼š
èªªæ˜ï¼šmetoclopramide å¢åŠ è…¸èƒƒè •å‹•ï¼Œå¸¸è¦‹å‰¯ä½œç”¨ç‚ºè…¹ç€‰è€Œéä¾¿ç§˜ã€‚
???

##### 114-2(28) +
```Question
ä¸‹åˆ—5-HTå—é«”ä¸­ï¼Œä½•è€…ä¸æ˜¯Gè›‹ç™½å¶è¯å—é«”ï¼ˆG protein-coupled receptorï¼‰ï¼Ÿ
```
(A) 5-HT1å—é«”
(B) 5-HT2å—é«”
(C) 5-HT3å—é«”
(D) 5-HT4å—é«”
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šC
èªªæ˜ï¼š5-HT3 ç‚ºligand-gated ion channelï¼Œå…¶é¤˜çš†ç‚ºGPCRã€‚
???

##### 114-2(29) +
```Question
ä¸‹åˆ—é—œæ–¼acetaminophenæ¯’æ€§ä¹‹æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) å–®æ¬¡å£æœ15å…‹ä»¥ä¸Šå¯èƒ½è‡´å‘½
(B) è—¥ç‰©ä¸­æ¯’æ™‚çš„è§£æ¯’åŠ‘ç‚ºç¶­ç”Ÿç´ C
(C) å¯èƒ½å¼•èµ·è‚æ¯’æ€§
(D) å¯èƒ½åŠ é‡NSAIDè—¥ç‰©å°èƒƒè…¸é“çš„æ¯’æ€§
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB
èªªæ˜ï¼šacetaminophen è§£æ¯’åŠ‘ç‚ºN-acetylcysteineï¼Œç¶­ç”Ÿç´ Cç„¡æ•ˆã€‚
???

##### 114-2(30) +
```Question
Dantroleneæ˜¯è‡¨åºŠå¸¸ç”¨ä¹‹éª¨éª¼è‚Œé¬†å¼›åŠ‘ï¼Œä¸‹åˆ—æœ‰é—œè©²è—¥çš„æ•˜è¿°ä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) å£æœç„¡æ³•å¸æ”¶ï¼Œåªèƒ½éœè„ˆæ³¨å°„çµ¦è—¥
(B) å…¶ä½œç”¨æ©Ÿåˆ¶ç‚ºå¹²æ“¾è‚Œæ¼¿ç¶²å…§éˆ£é›¢å­çš„é‡‹æ”¾
(C) å¯æ²»ç™‚éº»é†‰åŠ‘å¼•èµ·çš„æƒ¡æ€§é«˜ç†±ï¼ˆmalignant hyperthermiaï¼‰
(D) å¯èƒ½æœƒå¼•èµ·è‚ç‚ï¼ˆhepatitisï¼‰ç­‰å‰¯ä½œç”¨
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šdantrolene å¯å£æœå¸æ”¶ï¼Œä¹Ÿæœ‰éœè„ˆåŠ‘å‹ï¼›A é¸é …éŒ¯èª¤ã€‚
???

##### 114-2(31) +
```Question
ä¸‹åˆ—æŠ—æ†‚é¬±è—¥ç‰©ï¼ˆantidepressantsï¼‰ä¸­ï¼Œä½•è€…å±¬æ–¼é¸æ“‡æ€§è¡€æ¸…ç´ å›æ”¶æŠ‘åˆ¶åŠ‘ï¼ˆselective serotonin reuptake inhibitorï¼‰ï¼Ÿ
```
(A) mirtazapine
(B) fluoxetine
(C) trazodone
(D) duloxetine
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB
èªªæ˜ï¼šfluoxetine ç‚ºå…¸å‹SSRIï¼Œä¸»è¦æŠ‘åˆ¶è¡€æ¸…ç´ å›æ”¶ï¼Œç”¨æ–¼æ²»ç™‚æ†‚é¬±èˆ‡ç„¦æ…®ã€‚
???

##### 114-2(32) +
```Question
ä¸‹åˆ—è—¥ç‰©ä¸­ï¼Œä½•è€…ä½œç”¨æ–¼ä¸­æ¨ç¥ç¶“è¸é¹¼æ€§å—é«”ï¼Œå¯é€éé˜»æ–·å°¼å¤ä¸ï¼ˆnicotineï¼‰æ‰€å¼•èµ·çš„å¤šå·´èƒºé‡‹æ”¾è€Œä½œç‚ºæˆ’è¸ç”¨è—¥ï¼Ÿ
```
(A) bupropion
(B) rimonabant
(C) varenicline
(D) nortriptyline
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šC (è¿‘å¹´è€ƒå¤)
èªªæ˜ï¼švarenicline ç‚ºéƒ¨åˆ†nAChRè‡´æ•ˆåŠ‘ï¼Œå¯é˜»æ–·å°¼å¤ä¸å¼•ç™¼çš„å¤šå·´èƒºé‡‹æ”¾ï¼Œå”åŠ©æˆ’è¸ã€‚
???

##### 114-2(33) +
```Question
é—œæ–¼é®éœå®‰çœ è—¥zolpidemçš„ç‰¹æ€§ï¼Œä¸‹åˆ—ä½•è€…æ­£ç¢ºï¼Ÿ
```
(A) è—¥ç†ä½œç”¨æ¨™çš„æ˜¯GABAAå—é«”
(B) è§£æ¯’åŠ‘ç‚ºflurazepam
(C) æœƒè¢«æ°§åŒ–æˆå…·æœ‰æ´»æ€§ä»£è¬ç”¢ç‰©
(D) å…¶ä»£è¬é…µç´ æ˜¯aldehyde dehydrogenase
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA (å¯èƒ½çœ¼å¹¹ç­”åˆ°B)
èªªæ˜ï¼šzolpidem ç‚ºnon-BZDé¡é®éœè—¥ï¼Œé¸æ“‡æ€§ä½œç”¨æ–¼GABAAå—é«”ä¹‹BZ1äºå‹ã€‚
???

##### 114-2(34) +
```Question
ä¸‹åˆ—é‚£ä¸€ç¨®æŠ—ç™²ç™‡è—¥ç‰©ï¼Œå…¶åŒ–å­¸çµæ§‹èˆ‡GABAé¡ä¼¼ï¼Œå°æ–¼å±€éƒ¨æ€§ç™²ç™‡ï¼ˆfocal seizuresï¼‰çš„æ²»ç™‚ï¼Œå…·æœ‰ä¸éŒ¯çš„æ•ˆæœï¼Ÿ
```
(A) topiramate
(B) gabapentin
(C) felbamate
(D) tiagabine
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB
èªªæ˜ï¼šgabapentin çµæ§‹é¡ä¼¼GABAï¼Œä½†ä¸ç›´æ¥ä½œç”¨æ–¼GABAå—é«”ï¼Œç”¨æ–¼éƒ¨åˆ†æ€§ç™²ç™‡æ•ˆæœè‰¯å¥½ã€‚
???

##### 114-2(35)
```Question
ä¸‹åˆ—é‚£ä¸€ç¨®è—¥ç‰©ä¸é©æ–¼æ²»ç™‚èºé¬±ç—‡ï¼ˆbipolar affective disorderï¼‰ï¼Ÿ
```
(A) lithium carbonate
(B) valproic acid
(C) phenytoin
(D) carbamazepine
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šB (GGäº†)
èªªæ˜ï¼šphenytoin ç‚ºæŠ—ç™²ç™‡è—¥ï¼Œç„¡ç©©å®šæƒ…ç·’æ•ˆæœï¼Œä¸é©ç”¨æ–¼èºé¬±ç—‡æ²»ç™‚ã€‚
???

##### 114-2(36)
```Question
ä¸€ä½50æ­²çš„ç”·æ€§èºé¬±ç—‡æ‚£è€…ï¼ŒåŒæ™‚å…·æœ‰è…çµ²çƒè…ç‚ï¼ˆglomerulonephritisï¼‰çš„ç—…å²ã€‚å› å…¶èºé¬±ç—‡éå¸¸åš´é‡éœ€è¦æ¥å—è—¥ç‰©çš„æ²»ç™‚ï¼Œä¸‹åˆ—é‚£ä¸€ç¨®è—¥ç‰©æœ€é©åˆå…¶ä½¿ç”¨ï¼Ÿ
```
(A) imipramine
(B) carbamazepine
(C) lithium carbonate
(D) buspirone
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šD (NMSL)
èªªæ˜ï¼šlithium ä¸»è¦ç¶“è…æ’é™¤ï¼Œè…ç‚æ‚£è€…ç¦ç”¨ï¼›carbamazepine å¯ç”¨æ–¼èºé¬±ç—‡ï¼Œå°è…æ¯’æ€§è¼ƒä½ã€‚
???

##### 114-2(37) +
```Question
ä¸‹åˆ—é‚£ä¸€ç¨®æŠ—ç™²ç™‡è—¥ç‰©ä¸é©ç”¨æ–¼å¤±ç¥æ€§å°ç™¼ä½œï¼ˆabsence seizuresï¼‰ï¼Ÿ
```
(A) ethosuximide
(B) phenytoin
(C) lamotrigine
(D) valproic acid
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB
èªªæ˜ï¼šphenytoin å°absence seizure ç„¡æ•ˆï¼Œå¯èƒ½åŠ é‡ç—‡ç‹€ï¼›ethosuximide å’Œ valproic acid ç‚ºé¦–é¸ã€‚
???

##### 114-2(38) +
```Question
ä¸‹åˆ—ä½•ç¨®å¤©ç„¶ç‰©æˆ–ä¸­è‰è—¥æˆåˆ†å¯è—‰ç”±æŠ‘åˆ¶serotonin reuptakeï¼Œæœ‰åŠ©æ–¼æ†‚é¬±ç—‡æ‚£è€…çš„ç—…æƒ…æ”¹å–„ï¼Ÿ
```
(A) St. John's wort
(B) yohimbe bark
(C) taxol
(D) resveratrol
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šè–ç´„ç¿°è‰ï¼ˆSt. John's wortï¼‰å¯æŠ‘åˆ¶è¡€æ¸…ç´ å›æ”¶ï¼Œå…·æœ‰é¡ä¼¼æŠ—æ†‚é¬±ä½œç”¨ã€‚
???

##### 114-2(39)
```Question
è¨±å¤šä¸­è‰è—¥éƒ½å…·æœ‰æŠ—è¡€å°æ¿ï¼ˆanti-plateletï¼‰çš„è—¥ç†æ´»æ€§ï¼Œä½†ä¸åŒ…æ‹¬ä¸‹åˆ—ä½•è€…ï¼Ÿ
```
(A) ginseng
(B) milk thistle
(C) garlic
(D) ginkgo
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB (å¯èƒ½æ˜¯A)
èªªæ˜ï¼šmilk thistle ä¸»è¦å…·ä¿è‚ä½œç”¨ï¼Œæœªè¦‹é¡¯è‘—æŠ—è¡€å°æ¿åŠŸèƒ½ï¼›å…¶é¤˜ä¸‰è€…æœ‰æŠ‘åˆ¶è¡€å°æ¿èšé›†ä¹‹å ±å‘Šã€‚
???

##### 114-2(40) +
```Question
ä¸‹åˆ—æœ‰é—œliposome-DNAè¼‰é«”ç³»çµ±åšåŸºå› è½‰æ®–ï¼ˆgene transferï¼‰ä¹‹æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) ä¸å®¹æ˜“ç”Ÿç”¢ï¼ˆdifficult productionï¼‰
(B) ä½è½‰æ®–æ•ˆç‡ï¼ˆlow efficiencyï¼‰
(C) çŸ­æ™‚é–“è¡¨é”ï¼ˆtransient expressionï¼‰
(D) è¼ƒä¸æ˜“ç”¢ç”Ÿå…ç–«åæ‡‰ï¼ˆlow immune reactionï¼‰
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šliposome ç³»çµ±è£½å‚™ç°¡ä¾¿ï¼Œä¸”å…·ä½å…ç–«åŸæ€§ï¼Œä½†æ•ˆç‡ä½ã€è¡¨é”çŸ­æš«ã€‚
???

##### 114-2(41) +
```Question
ä¸‹åˆ—æŠ—é«”å¶è¯è—¥ç‰©ï¼ˆADCï¼‰çš„é€£æ¥å­ï¼ˆlinkerï¼‰ï¼Œä½•è€…ç‚ºglutathione-sensitiveï¼Ÿ
```
(A)![[Pasted image 20250721115317.png]]
(B)![[Pasted image 20250721115311.png]]
(C)![[Pasted image 20250721115308.png]]
(D)![[Pasted image 20250721115259.png]]
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šD (çœŸæ²’æ•‘äº†ï¼ŒåŸºæœ¬é¡Œ)
æ€è€ƒæ–¹å‘ï¼š
å¯å›æƒ³ glutathione-sensitive linker å¸¸å…·æœ‰ã€Œå¯è¢«é‚„åŸã€çš„ç‰¹æ€§ï¼Œå°¤å…¶æ˜¯ *disulfide bondï¼ˆ-S-S-ï¼‰* çµæ§‹ï¼Œæœƒåœ¨è…«ç˜¤ç´°èƒä¸­é«˜æ¿ƒåº¦é‚„åŸæ€§ç’°å¢ƒä¸‹æ–·è£‚ï¼Œé‡‹å‡ºæ¯’ç‰©ã€‚çœ‹åˆ°æœ‰é›™ç¡«éµå³å¯æ‡·ç–‘èˆ‡æ­¤æœ‰é—œã€‚
???

##### 114-2(42)
```Question
åŒ–ç™‚è—¥ç‰©irinotecanï¼ˆçµæ§‹å¦‚ä¸‹åœ–ï¼‰å±¬å‰é©…è—¥ï¼ˆprodrugï¼‰ï¼Œé«”å…§ä»£è¬çš„æ´»æ€§æˆåˆ†ç‚ºSN-38ï¼Œå…¶è¢«è¨­è¨ˆæˆå‰é©…è—¥çš„ä¸»è¦ç›®çš„ç‚ºä½•ï¼Ÿ
```
![[Pasted image 20250721115251.png]]
(A) å¢åŠ æ°´æº¶æ€§
(B) å¢åŠ è„‚æº¶æ€§
(C) å¢åŠ é¸æ“‡æ€§ï¼Œé™ä½å‰¯ä½œç”¨
(D) å¢åŠ ç´°èƒæ¯’æ®ºä½œç”¨
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šC (èª°çŸ¥é“é˜¿)
æ€è€ƒæ–¹å‘ï¼š
irinotecan æ˜¯æ°´æº¶æ€§çš„å‰é©…è—¥ï¼Œè¢«è‚è‡Ÿçš„ *carboxylesterase* æ´»åŒ–ç‚º SN-38ã€‚ä½ å¯ä»¥æ ¹æ“šå‰é©…è—¥çš„è¨­è¨ˆç›®çš„ï¼Œæ€è€ƒæ˜¯ç‚ºäº†æ”¹å–„è—¥å‹•å­¸é‚„æ˜¯é™ä½æ¯’æ€§â€”â€”é€šå¸¸èˆ‡ *æº¶è§£æ€§* æˆ– *çµ„ç¹”å°ˆä¸€æ€§* æœ‰é—œã€‚
???

##### 114-2(43)
```Question
ä¾æ“šç–«è‹—çš„ç¨®é¡å€åˆ†ï¼Œå¸‚å”®13åƒ¹è‚ºç‚éˆçƒèŒç–«è‹—å±¬æ–¼ä¸‹åˆ—é‚£ä¸€é¡ï¼Ÿ
```
(A) æ´»ç–«è‹—ï¼ˆlive vaccineï¼‰
(B) æ¬¡å–®å…ƒç–«è‹—ï¼ˆsubunit vaccineï¼‰
(C) mRNAç–«è‹—
(D) çµåˆå‹ç–«è‹—ï¼ˆconjugate vaccineï¼‰
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šB (ä¸çŸ¥é“å°±æ˜¯ä¸çŸ¥é“)
æ€è€ƒæ–¹å‘ï¼š
é—œéµè©æ˜¯ã€Œ13åƒ¹è‚ºç‚éˆçƒèŒç–«è‹—ã€ï¼Œé€šå¸¸è‚ºç‚éˆçƒèŒç–«è‹—æœƒé‡å° *è¢è†œå¤šé†£é«”*ï¼Œä½†å–®ä¸€å¤šé†£é«”æ•ˆæœå¼±ï¼Œéœ€èˆ‡è›‹ç™½è³ªçµåˆå½¢æˆã€Œçµåˆå‹ç–«è‹—ã€ä»¥ç”¢ç”Ÿè¼ƒä½³å…ç–«åæ‡‰ã€‚
???

##### 114-2(44)
```Question
Nusinersençµæ§‹ä¸­ï¼Œå«æœ‰ä¸‹åˆ—ä½•ç¨®å·²ä¿®é£¾çš„é¹¼åŸºï¼ˆmodified baseï¼‰ï¼Ÿ
```
(A)![[Pasted image 20250721115225.png]]
(B)![[Pasted image 20250721115222.png]]
(C)![[Pasted image 20250721115219.png]]
(D)![[Pasted image 20250721115216.png]]
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB (çŒœä¸­)
æ€è€ƒæ–¹å‘ï¼š
nusinersen æ˜¯ç”¨æ–¼è„Šé«“æ€§è‚Œè‚‰èç¸®ç—‡ï¼ˆSMAï¼‰çš„åç¾©å¯¡æ ¸è‹·é…¸ï¼ˆASOï¼‰ï¼Œæœƒä½¿ç”¨ã€Œæ ¸è‹·é…¸ä¿®é£¾ã€ä¾†å¢åŠ ç©©å®šæ€§èˆ‡æŠ—æ ¸é…¸é…¶ï¼Œä¾‹å¦‚ 2â€²-O-methoxyethylã€phosphorothioate linkage ç­‰ã€‚çœ‹é¸é …æ˜¯å¦æœ‰é¡ä¼¼çµæ§‹ã€‚
???

##### 114-2(45) +
```Question
ä¸‹åˆ—æœ‰æ©Ÿé…¸ï¼Œä½•è€…pKaå€¼ä»‹æ–¼4ï½5ï¼Ÿ
```
(A) phenol
(B) sulfonic acid
(C) sulfonimide
(D) arylcarboxylic acid
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šD/A
æ€è€ƒæ–¹å‘ï¼š
ç†Ÿè¨˜å¸¸è¦‹å®˜èƒ½åŸºçš„pKaç¯„åœï¼š

* phenolï¼šç´„ 10 ï¼ˆè¦èªçµæ§‹ï¼‰
* sulfonic acidï¼šéå¸¸é…¸ï¼ŒpKa ç´„ -1
* sulfonimideï¼špKa ç´„ 5\~7ï¼ˆå–æ±ºæ–¼å–ä»£åŸºï¼‰
* arylcarboxylic acidï¼ˆå¦‚ benzoic acidï¼‰ï¼špKa ç´„ 4.2
æ ¹æ“šé€™äº›è³‡è¨Šå³å¯åˆæ­¥åˆ¤æ–·ã€‚
???

##### 114-2(46)
```Question
äººé«”è‹¥ç¼ºä¹ä¸‹åˆ—ä½•ç¨®ä»£è¬èƒ½åŠ›ï¼Œå‰‡åœ¨ä½¿ç”¨irinotecanå¾Œï¼Œæ˜“é€ æˆåš´é‡å—œä¸­æ€§ç™½è¡€çƒç¼ºä¹ç—‡ï¼Ÿ
```
(A) glucuronidation
(B) sulfate conjugation
(C) acetylation
(D) hydrolysis
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šC (ä¸çŸ¥é“ï¼Œä½†æ‡‰è©²å¯ä»¥çŒœå¸¸è¦‹çš„ A å°±æ˜¯äº†)
èªªæ˜ï¼širinotecan ç¶“ UGT1A1 é€²è¡Œ glucuronidation ä»£è¬ï¼Œç¼ºä¹æ­¤é…µç´ ï¼ˆå¦‚ UGT1A1\*28 è®Šç•°ï¼‰æœƒå°è‡´ SN-38 ç´¯ç©ï¼Œå¢åŠ æ¯’æ€§ï¼ˆç‰¹åˆ¥æ˜¯å—œä¸­æ€§ç™½è¡€çƒç¼ºä¹ç—‡ï¼‰ã€‚
???

##### 114-2(47) - AIç­”éŒ¯
```Question
Cocaineç¶“æ°´è§£å¾Œï¼Œä¸æœƒç”¢ç”Ÿä¸‹åˆ—ä½•ç¨®ç”¢ç‰©ï¼Ÿ
```
(A) tropine
(B) benzoic acid
(C) ecgonine
(D) methanol
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA (è€ƒå¤)
èªªæ˜ï¼šå¯å¡å› ç¶“é…¯é…¶æ°´è§£å¾Œç”¢ç”Ÿ benzoic acid å’Œ ecgonine methyl esterï¼ˆæˆ– tropine ç›¸é—œç‰©ï¼‰ï¼Œä¸æœƒç”¢ç”Ÿ methanolã€‚
???

##### 114-2(48) +
```Question
ç‚ºé˜²æ­¢é€ æˆè‡´å‘½ï¼Œä¸‹åˆ—ä½•ç¨®äº¤æ„Ÿç¥ç¶“è—¥ç‰©ï¼Œä¸å»ºè­°ç”¨æ–¼æ€¥æ€§åš´é‡æ°£å–˜ï¼Ÿ
```
(A) epinephrine![[Pasted image 20250721115203.png]]
(B) formoterol![[Pasted image 20250721115157.png]]
(C) metaproterenol![[Pasted image 20250721115153.png]]
(D) salmeterol ![[Pasted image 20250721115032.png]]
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šD (å¯èƒ½æˆ‘å¾Œé¢æœ‰æ”¹)
èªªæ˜ï¼šsalmeterol ç‚ºé•·æ•ˆÎ²2è‡´æ•ˆåŠ‘ï¼ˆLABAï¼‰ï¼Œèµ·æ•ˆæ…¢ï¼Œä¸é©åˆç”¨æ–¼æ€¥æ€§ç™¼ä½œï¼Œåƒ…é©åˆé•·æœŸæ§åˆ¶ã€‚
???

##### 114-2(49) - AIç­”éŒ¯ +
```Question
ä¸‹åˆ—åˆ©å°¿åŠ‘å«æœ‰ä¹‹é›œç’°çµæ§‹ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) furosemideï¼šfuran
(B) methyclothiazideï¼šbenzothiadiazine-1,1-dioxide
(C) metolazoneï¼šquinolin-4-one
(D) acetazolamideï¼šthiadiazole
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šD (ä½ ä»–åª½)
èªªæ˜ï¼šacetazolamide çµæ§‹ç‚º thiadiazole-2-sulfonamideï¼Œé¸é … D é›–çœ‹ä¼¼å°ï¼Œä½†è‹¥é¸é …æè¿°èˆ‡çœŸå¯¦çµæ§‹ä¸ç¬¦å¯è¦–ç‚ºé™·é˜±ï¼Œå¯¦éš›ä¸Šæ˜¯æ­£ç¢ºçµæ§‹ï¼Œå› æ­¤æœ¬é¡Œç‚ºé™·é˜±é¡Œå‹ï¼Œéœ€ç‰¹åˆ¥æª¢æŸ¥é¸é …æè¿°æ˜¯å¦èˆ‡å®˜èƒ½åŸºåç¨±ä¸€è‡´ã€‚
???

##### 114-2(50)
```Question
ä¸‹åˆ—æœ‰é—œalfentanilä¹‹æ•˜è¿°ï¼Œä½•è€…æ­£ç¢ºï¼Ÿ
```
(A) å…·æœ‰tetrazolinoneç’°ï¼Œè„‚æº¶æ€§è¼ƒsufentanilé«˜
(B) alfentanilèˆ‡Î¼å—é«”ä¹‹è¦ªåŠ›è¼ƒmorphineå¼·25å€
(C) æ¯”sufentanilæ›´å¿«é€Ÿç©¿éBBB
(D) ç‚ºé¸æ“‡æ€§Îºå—é«”è‡´æ•ˆåŠ‘
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šB (æ²’è¾¦æ³•)
èªªæ˜ï¼šalfentanil ç‚ºé«˜è¦ªè„‚æ€§çŸ­æ•ˆ Î¼ å—é«”è‡´æ•ˆåŠ‘ï¼Œèµ·æ•ˆæ™‚é–“å¿«æ–¼ fentanyl åŠ sufentanilã€‚
???

##### 114-2(51)
```Question
ä¸‹åˆ—æœ‰é—œmorphineä¹‹æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) morphineè¼ƒmorphine-6-glucuronideå…·æœ‰å°opioid receptoræ›´é«˜è¦ªå’ŒåŠ›
(B) heroinç‚ºmorphineä¹‹å‰é©…è—¥ï¼ˆprodrugï¼‰
(C) codeineå¯ç¶“CYP3A4å‚¬åŒ–ä»£è¬æˆnorcodeine
(D) normorphineç‚ºmorphineé€²è¡ŒN-demethylationä¹‹ç”¢ç‰©
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šç¸½ä¹‹é€™é¡Œå°±æ˜¯åç›´è¦ºï¼Œåæ­£å°±æ˜¯éŒ¯äº†
èªªæ˜ï¼šmorphine-6-glucuronide å°Î¼-opioid receptor ä¹‹è¦ªå’ŒåŠ›èˆ‡æ´»æ€§çš†é«˜æ–¼ morphine æœ¬èº«ã€‚
???

##### 114-2(52)
```Question
ä¸‹åˆ—ä½•è€…æœ€ä¸å¯èƒ½ç‚ºnaloxoneçš„ä»£è¬ç‰©ï¼Ÿ
```
(A)![[Pasted image 20250721114929.png]]
(B)![[Pasted image 20250721114911.png]]
(C)![[Pasted image 20250721114857.png]]
(D)![[Pasted image 20250721114835.png]]
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šA (æ²’è¾¦æ³•)
æ€è€ƒæ–¹å‘ï¼š
naloxone ä¸»è¦ç¶“è‚è‡Ÿé‚„åŸåŠè‘¡è„é†£é†›é…¸åŒ–ï¼ˆglucuronidationï¼‰ä»£è¬ï¼Œå¸¸è¦‹ç”¢ç‰©åŒ…æ‹¬é‚„åŸå¾Œçš„alcohol formsèˆ‡å…¶glucuronideå‹æ…‹ã€‚è«‹è§€å¯Ÿé¸é …ä¸­æ˜¯å¦æœ‰çµæ§‹æ˜é¡¯ä¸åˆæˆæˆ–ä¸å…·è©²é…µç´ ä½œç”¨çµæœã€‚
???

##### 114-2(53)
```Question
Oxcarbazepineç¶“ä¸‹åˆ—ä½•ç¨®ä»£è¬åæ‡‰å¯å¾—licarbazepineï¼Ÿ
```
(A) é‚„åŸ
(B) é†¯åŒ–
(C) æ°´è§£
(D) æ°§åŒ–
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA (çŒœä¸­)
èªªæ˜ï¼šOxcarbazepine ç‚ºå‰é©…è—¥ï¼Œç¶“é‚„åŸç”Ÿæˆæ´»æ€§ä»£è¬ç‰© licarbazepineï¼ˆ10-monohydroxy derivativeï¼‰ã€‚
???

##### 114-2(54) +
```Question
ä¸‹åˆ—ä½•è€…ç‚ºethosuximideä¹‹ä¸»è¦ä»£è¬ç‰©ï¼Ÿ
```
(A)![[Pasted image 20250721114752.png]]
(B)![[Pasted image 20250721114735.png]]
(C)![[Pasted image 20250721114724.png]]
(D)![[Pasted image 20250721114702.png]]
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šB
æ€è€ƒæ–¹å‘ï¼š
ethosuximide ç‚º succinimide è¡ç”Ÿç‰©ï¼Œå…¶ä¸»è¦ä»£è¬å½¢å¼ç‚º 3-ç¾¥åŸºåŒ–ï¼ˆ3-hydroxylationï¼‰åŠå¾ŒçºŒå…±è»›åæ‡‰ã€‚è«‹è§€å¯Ÿæ˜¯å¦æœ‰3ä½é»ç”¢ç”Ÿhydroxylæˆ–ç›¸å°æ‡‰çš„ä»£è¬å‹æ…‹ã€‚
???

##### 114-2(55) - AIç­”éŒ¯ å¯ä»¥çˆ­å–(ä½†æˆ‘å°) +
```Question
Lacosamideï¼ˆçµæ§‹å¦‚ä¸‹åœ–ï¼‰å±¬æŠ—ç™²ç™‡è—¥ç‰©ï¼Œå…¶è—¥ç‰©è¨­è¨ˆç†å¿µæ˜¯åŸºæ–¼ç™¼ç¾ä½•ç¨®å…·æœ‰æŠ—ç™²ç™‡æ´»æ€§ä¹‹èƒºåŸºé…¸è¡ç”Ÿç‰©ï¼Ÿ
```
![[Pasted image 20250721114525.png]]
(A) alanine
(B) cysteine
(C) serine
(D) threonine
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šLacosamide ç‚º D-serine è¡ç”Ÿç‰©ï¼Œå…¶è¨­è¨ˆåŸºæ–¼ N-acetyl-D-serine é¡çµæ§‹ï¼Œä¿ç•™éƒ¨åˆ†ç¥ç¶“ä¿è­·èˆ‡æŠ—ç™²ç™‡æ´»æ€§ã€‚
???

##### 114-2(56)
```Question
å°‡melatoninçµæ§‹å¼ä¸­çš„indoleç’°ï¼Œç¶“ä¸‹åˆ—ä½•ç¨®çµæ§‹å–ä»£å¯å¾—agomelatineï¼Ÿ
```
(A) quinoline
(B) benzofuran
(C) benzothiazole
(D) naphthalene
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šB (çœŸç„¡æ³•)
èªªæ˜ï¼šagomelatine ç‚ºmelatoninçš„çµæ§‹é¡ä¼¼ç‰©ï¼Œå…¶ä¸­indoleè¢«naphthaleneå–ä»£ï¼Œä»¥å»¶é•·ä½œç”¨ä¸¦æ”¹è®Šä»£è¬ç‰¹æ€§ã€‚
???

##### 114-2(57)
```Question
ä¸‹åˆ—dopamineå—é«”è‡´æ•ˆåŠ‘ä¸­ï¼Œä½•è€…é€šå¸¸ä¸ç”¨æ–¼restless leg syndromeçš„æ²»ç™‚ï¼Ÿ
```
(A) rotigotine
(B) ropinirole
(C) pramipexole
(D) cabergoline
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šB (éŒ¯äº†GG)
èªªæ˜ï¼šcabergoline ç‚ºé•·æ•ˆD2è‡´æ•ˆåŠ‘ï¼Œä¸»è¦ç”¨æ–¼é«˜æ³Œä¹³ç´ è¡€ç—‡ï¼Œè¼ƒå°‘ç”¨æ–¼RLSï¼Œå‰ä¸‰è€…çš†ç‚ºRLSæ²»ç™‚å¸¸ç”¨è—¥ã€‚
???

##### 114-2(58) æ©Ÿè»Šé¡Œ
```Question
ä¸‹åˆ—ä½•è€…åœ¨é«”å…§ç”ŸæˆæŠ—åŸæ€§è›‹ç™½ï¼ˆantigenic proteinï¼‰çš„æ¯”ä¾‹æœ€ä½ï¼Œå› æ­¤è‚æ¯’æ€§æœ€å°ï¼Ÿ
```
(A) halothane
(B) enflurane
(C) isoflurane
(D) sevoflurane
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šC (ISOä¸æ˜¯èˆ‡çœ¾ä¸åŒæ‰€ä»¥æœ€ä½å—?????)
èªªæ˜ï¼šsevoflurane åœ¨é«”å…§ä»£è¬ç‡ä½ï¼Œç”Ÿæˆçš„ä»£è¬ç”¢ç‰©å°‘ï¼Œæ•…è‚æ¯’æ€§é¢¨éšªä¹Ÿè¼ƒä½ã€‚
???

##### 114-2(59) +
```Question
åˆ©å°¿åŠ‘chlorthalidoneå…·æœ‰ä¸‹åˆ—ä½•ç¨®çµæ§‹ï¼Ÿ
```
(A) spirolactone ring
(B) 1-oxo-indoline
(C) phthalimidine
(D) benzothiadiazine
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šC
èªªæ˜ï¼šchlorthalidone ç‚ºthiazide-likeåˆ©å°¿åŠ‘ï¼Œå…¶æ ¸å¿ƒç‚ºphthalimidineçµæ§‹ï¼Œèˆ‡å…¸å‹thiazideä¸åŒã€‚
???

##### 114-2(60) +
```Question
éˆ£é›¢å­æ˜¯èˆ‡prothrombinä½•ç¨®çµæ§‹çµåˆå¾Œï¼Œè€Œæ´»åŒ–å…¶å‡è¡€ä½œç”¨ï¼Ÿ
```
(A) Î³â€“carboxyglutamate
(B) succinic acid
(C) lysine
(D) arginine
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šB (ç„¡æ³•)
èªªæ˜ï¼švitamin K åƒèˆ‡ç”Ÿæˆçš„Î³â€“carboxyglutamateæ®˜åŸºå¯èˆ‡CaÂ²âºçµåˆï¼Œä½¿prothrombinå¸é™„æ–¼ç´°èƒè†œè¡¨é¢é€²è€Œæ´»åŒ–ã€‚
???

##### 114-2(61) +
```Question
ä¸‹åˆ—ä½•ç¨®è—¥ç‰©ï¼Œå¯æ²»ç™‚é›†å°¿ç®¡ä¸Šçš®çš„éˆ‰é›¢å­é€šé“éåº¦æ´»åŒ–é€ æˆä¹‹Liddle syndromeï¼Ÿ
```
(A) canrenone
(B) furosemide
(C) amiloride
(D) dorzolamide
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šC
èªªæ˜ï¼šLiddle syndrome ç‚ºENaCï¼ˆepithelial sodium channelï¼‰éåº¦æ´»åŒ–ï¼Œamiloride ç‚ºENaCæŠ‘åˆ¶åŠ‘ï¼Œæ˜¯é¦–é¸è—¥ç‰©ã€‚
???

##### 114-2(62)
```Question
ä¸‹åˆ—æœ‰é—œåˆ©å°¿åŠ‘eplerenoneçš„æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) å…·9Î±,11Î±-epoxyåŸº
(B) å…·spirolactoneç’°
(C) å°mineralocorticoidå—é«”ä¹‹è¦ªå’ŒåŠ›æ¯”spironolactoneå¼·
(D) ä¸»è¦ç¶“CYP3A4ä»£è¬
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šç¸½ä¹‹å°±æ˜¯éŒ¯ (å¥½åƒè…¦è¡é¸D)
èªªæ˜ï¼šeplerenone ç‚ºé¸æ“‡æ€§MRæ‹®æŠ—åŠ‘ï¼Œä½†å°å—é«”è¦ªå’ŒåŠ›ä½æ–¼ spironolactoneï¼Œå„ªé»ç‚ºå‰¯ä½œç”¨è¼ƒå°‘ã€‚
???

##### 114-2(63)
```Question
ä¸‹åˆ—æœ‰é—œthiazideåˆ©å°¿åŠ‘SARçš„æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ
```
![[Pasted image 20250721114504.png]]
(A) N-2ä½å°å…¥alkylåŸºï¼Œæœ‰åˆ©å¢é•·è—¥æ•ˆæ™‚é–“
(B) C-3èˆ‡N-4ä¹‹é–“è‹¥ç‚ºå–®éµï¼Œå…¶åˆ©å°¿æ•ˆæœæ¸›å¼±
(C) C-6ä½é€šå¸¸å°å…¥æ‹‰é›»å­åŸºåœ˜
(D) C-7ä½é€šå¸¸å…·sulfonamideåŸºåœ˜
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šA è¨˜éŒ¯äº†
èªªæ˜ï¼šthiazide çš„æ´»æ€§èˆ‡C3-N4ä¹‹é–“çš„**é›™éµ**ç„¡é—œï¼Œäº‹å¯¦ä¸Šã€Œhydrothiazideã€ç‚ºé£½å’Œå‹ä»å…·æ´»æ€§ï¼ŒBé¸é …ä¸æ­£ç¢ºã€‚
???

##### 114-2(64) æ©Ÿè»Šé¡Œ
```Question
ä¸‹åˆ—HMG-CoAé‚„åŸé…¶æŠ‘åˆ¶åŠ‘ä¸­ï¼Œä½•è€…è„‚æº¶æ€§æœ€ä½ï¼Ÿ
```
(A) lovastatin
(B) simvastatin
(C) fluvastatin
(D) rosuvastatin
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šC (æ€éº¼æœƒ?) é€™ä¹Ÿæ˜¯ 2é¸1
èªªæ˜ï¼šrosuvastatin ç‚ºæ¥µæ€§è¼ƒé«˜çš„statinï¼Œä¸»è¦ä½œç”¨æ–¼è‚è‡Ÿï¼Œè„‚æº¶æ€§æœ€ä½ã€ä¹Ÿè¼ƒå°‘ç©¿éè¡€è…¦éšœå£ã€‚
???

##### 114-2(65)
```Question
ä¸‹åˆ—æœ‰é—œtamoxifenä¹‹æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) ç‚ºå‰é©…è—¥ï¼ˆprodrugï¼‰
(B) ä¸»è¦é CYP3A4æ´»åŒ–
(C) 4-hydroxy N-desmethyl tamoxifenç‚ºå…¶æ´»æ€§ä»£è¬ç‰©
(D) 4-hydroxytamoxifenç‚ºå…¶æ´»æ€§ä»£è¬ç‰©
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB (å¥½åƒæ˜¯?)
èªªæ˜ï¼štamoxifen ä¸»è¦ç”± **CYP2D6** ä»£è¬ç”Ÿæˆæ´»æ€§ä»£è¬ç‰©ï¼ŒCYP3A4 åƒèˆ‡å…¶ä»–æ¬¡è¦è·¯å¾‘ã€‚
???

##### 114-2(66) +
```Question
ç”²ç‹€è…ºç´ ï¼ˆçµæ§‹é€šå¼å¦‚ä¸‹åœ–ï¼‰ï¼Œå…¶ä¸­O-linkageåœ¨ç”Ÿåˆæˆçš„éç¨‹ä¸­æ˜¯ç”±ä¸‹åˆ—ä½•ç¨®é…µç´ å»ºæ§‹è€Œæˆï¼Ÿ
```
![[Pasted image 20250721114448.png]]
(A) tyrosine hydroxylase
(B) thyroperoxidase
(C) cyclooxygenase
(D) lipoxygenase
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB
èªªæ˜ï¼šthyroperoxidaseï¼ˆTPOï¼‰è² è²¬å‚¬åŒ–thyroglobulinä¸­tyrosineæ®˜åŸºçš„ç¢˜åŒ–èˆ‡è€¦åˆåæ‡‰ï¼ˆO-linkï¼‰ï¼Œå½¢æˆT3èˆ‡T4ã€‚
???

##### 114-2(67) +
```Question
Glucagonæ˜¯ç”±è˜­æ°å°å³¶çš„ä½•ç¨®ç´°èƒåˆ†æ³Œï¼Ÿ
```
(A) Î±
(B) Î²
(C) Î³
(D) Î´
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šèƒ°è‡ŸÎ±ç´°èƒåˆ†æ³Œglucagonï¼›Î²ç´°èƒåˆ†æ³Œinsulinï¼ŒÎ´ç´°èƒåˆ†æ³Œsomatostatinã€‚
???

##### 114-2(68) - AIç­”éŒ¯
```Question
Norethindroneï¼ˆçµæ§‹å¦‚ä¸‹åœ–ï¼‰æœ‰é—œå…¶é»ƒé«”ç´ ï¼ˆprogestinï¼‰æ´»æ€§ä¹‹æ•˜è¿°ï¼Œä¸‹åˆ—ä½•è€…éŒ¯èª¤ï¼Ÿ
```
![[Pasted image 20250721114425.png]]
(A) Î”4é›™éµæ”¹æˆÎ”5(10)é›™éµï¼Œæœƒå¤±å»æ´»æ€§
(B) C-10è‹¥å°å…¥CH3ï¼Œæœƒå…·æœ‰é›„æ€§ç´ çš„æ´»æ€§
(C) C-18ä¹‹CH3æ”¹æˆC2H5ï¼Œæœƒæé«˜æ´»æ€§
(D) C-21è‹¥å°å…¥Clï¼Œæœƒæé«˜æ´»æ€§
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šD (æ€éº¼æœƒ?)
èªªæ˜ï¼šC-18 çš„å–ä»£åŸºè‹¥éå¤§ï¼ˆå¦‚ C2H5ï¼‰æœƒé™ä½é»ƒé«”ç´ æ´»æ€§ï¼ŒC é¸é …éŒ¯èª¤ã€‚
???

##### 114-2(69) - AIç­”éŒ¯
```Question
ä¸‹åˆ—æœ‰é—œetodolacä¹‹æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) é¸æ“‡æ€§æŠ‘åˆ¶COX-2é«˜æ–¼COX-1ï¼Œå› æ­¤ç›¸å°ä¸€èˆ¬NSAIDçš„è…¸èƒƒå‰¯ä½œç”¨è¼ƒä½
(B) ä¸»è¦çš„æ´»æ€§ä¾†è‡ªæ–¼å…¶S-(+)ç•°æ§‹ç‰©
(C) çµæ§‹å…·æœ‰furanocarboxylic acid
(D) å…¶æŠ—ç‚æ´»æ€§æ¯”indomethacinä½
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šA (æ²’çœ‹éé€™è—¥)
èªªæ˜ï¼šetodolac ç‚ºå…·COX-2åé¸æ“‡æ€§çš„NSAIDï¼ŒæŠ—ç™¼ç‚æ•ˆåŠ›èˆ‡indomethacinç›¸ç•¶ï¼Œç”šè‡³æœ‰äº›ç ”ç©¶é¡¯ç¤ºæ•ˆæœæ›´ä½³ã€‚
???

##### 114-2(70)
```Question
ä¸‹åˆ—æœ‰é—œcetirizineåŠdesloratadineä¹‹æ•˜è¿°ï¼Œä½•è€…æ­£ç¢ºï¼Ÿ
```
(A) çš†ç‚ºå…©æ€§é›¢å­ï¼ˆzwitterionicï¼‰åˆ†å­ï¼Œä¸æ˜“é€²å…¥CNS
(B) loratadineçš„æŠ—çµ„ç¹”èƒºæ´»æ€§å¤§æ–¼desloratadine
(C) çš†ä»¥è—¥ç‰©åŸå‹æ’é™¤ç‚ºä¸»
(D) levocetirizineæ˜¯cetirizineçš„R-enantiomer
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šä¸ç¢ºå®šæ˜¯ä¸æ˜¯ç­”å°
èªªæ˜ï¼šlevocetirizine ç‚º cetirizine çš„ R-å°æ˜ ç•°æ§‹ç‰©ï¼Œå…·è¼ƒå¼·æ´»æ€§ï¼›å…¶ä»–é¸é …æè¿°ä¸æ­£ç¢ºæˆ–æ··æ·†ä»£è¬ç‰¹æ€§ã€‚
???

##### 114-2(71) +
```Question
ä¸‹åˆ—ä½•è€…ç‚ºæŠ—æ°£å–˜è—¥zileutonä½œç”¨æ¨™çš„ï¼Ÿ
```
(A) 5-lipoxygenase
(B) 12-lipoxygenase
(C) cyclooxygenase 1
(D) cyclooxygenase 2
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šA
èªªæ˜ï¼šzileuton ç‚º5-lipoxygenaseæŠ‘åˆ¶åŠ‘ï¼Œé˜»æ­¢ç™½ä¸‰çƒ¯ï¼ˆleukotrieneï¼‰ç”Ÿæˆï¼Œç”¨æ–¼æ°£å–˜æ§åˆ¶ã€‚
???

##### 114-2(72)
```Question
ä¸‹åˆ—cephalosporinsçš„å‰é©…è—¥å‹å¼ï¼Œä½•è€…æœ€ä¸æ˜“åœ¨é«”å…§æ´»åŒ–ï¼Ÿ
```
(A)![[Pasted image 20250721114414.png]]
(B)![[Pasted image 20250721114411.png]]
(C)![[Pasted image 20250721114408.png]]
(D)![[Pasted image 20250721114405.png]]
?
ç­”æ¡ˆï¼šA
æˆ‘çš„å›ç­”ï¼šC (å¤ªé›£äº†ï¼Œç­”ä¸äº†)
æ€è€ƒæ–¹å‘ï¼š
cephalosporin å‰é©…è—¥ï¼ˆå¦‚é…¯åŒ–å‹ï¼‰é€šå¸¸éœ€ç¶“é…¯é…¶æ°´è§£è½‰ç‚ºæ´»æ€§å½¢å¼ã€‚è‹¥çµæ§‹ç‚º**å¼·å…±è»›çµæ§‹ã€ä¸æ˜“æ°´è§£é…¯é¡**æˆ–ç„¡æ³•æœ‰æ•ˆé‡‹æ”¾ç¾§é…¸åŸºï¼Œå‰‡ä»£è¡¨æ´»åŒ–æ•ˆç‡å·®ã€‚å¯è§€å¯Ÿæ˜¯å¦æœ‰ bulky é…¯ã€ç©©å®šèŠ³é¦™çµæ§‹ç­‰ã€‚
???

##### 114-2(73) +
```Question
ä¸‹åˆ—æœ‰é—œechinocandiné¡æŠ—çœŸèŒè—¥ä¹‹æ•˜è¿°ï¼Œä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) çµæ§‹å…·è„‚è‚½ï¼ˆlipopeptidesï¼‰
(B) æŠ‘åˆ¶Î²-1,3-glucan synthase
(C) é˜»æ­¢çœŸèŒç´°èƒå£åˆæˆ
(D) micafunginè¼ƒå®‰å®šï¼Œä¸æ˜“è¢«é…µç´ ä»£è¬
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šC (é€™ç®—æ˜¯åŸºæœ¬é¡Œ)
èªªæ˜ï¼šmicafungin çµæ§‹æœ‰ sulfonate åŸºåœ˜ï¼Œå®¹æ˜“ä»£è¬ï¼›ç›¸è¼ƒè€Œè¨€ï¼Œanidulafungin ç‚ºéé…µç´ æ€§é™è§£ï¼Œè¼ƒç©©å®šã€‚
???

##### 114-2(74)
```Question
ä¸‹åˆ—ä½•è€…å°T315I mutantçš„Bcr-Abl kinaseå…·æœ‰æŠ‘åˆ¶ä½œç”¨ï¼Ÿ
```
(A) dasatinib
(B) nilotinib
(C) ponatinib
(D) imatinib
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šD (å€‹è«–ç„¡æ³•)
èªªæ˜ï¼šT315I ç‚º gatekeeper çªè®Šï¼Œæœƒé€ æˆå¤šæ•¸ tyrosine kinase inhibitor å¤±æ•ˆï¼Œå”¯æœ‰ ponatinib å°å…¶å…·æŠ‘åˆ¶ä½œç”¨ã€‚
???

##### 114-2(75) - AIç­”éŒ¯
```Question
åœ¨tyrosine kinase inhibitorsçµæ§‹ä¸­ï¼ŒæŸäº›åŸºåœ˜å¸¸ç”¨ä¾†å¢åŠ æ°´æº¶è§£åº¦ï¼Œä¸‹åˆ—ä½•è€…éŒ¯èª¤ï¼Ÿ
```
(A) piperazine ring of imatinib
(B) piperidine ring of ponatinib
(C) imidazole ring of nilotinib
(D) methylsulfone of lapatinib
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼š D (ä¸è¡Œç„¡æ³•)
èªªæ˜ï¼šnilotinib çµæ§‹ä¸­ä¸å…· imidazole ringï¼Œæ­¤é¸é …éŒ¯èª¤ï¼›å…¶ä»–é¸é …çš†ç‚ºå¢åŠ æ°´æº¶æ€§ä¹‹å®˜èƒ½åŸºè¨­è¨ˆã€‚
???

##### 114-2(76) - å®‰å¹³é€šéˆ
```Question
ä¸‹åˆ—ä½•ç¨®è—¥ç‰©å¯èˆ‡aromatase inhibitorä½µç”¨ï¼Œç”¨åœ¨æ²»ç™‚HER2â»è½‰ç§»æ€§ä¹³ç™Œï¼ˆHER2â» MBCï¼‰ï¼Ÿ
```
(A) neratinib
(B) trastuzumab
(C) pertuzumab
(D) palbociclib
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šB (å‚»çœ¼æ²’å¯«åˆ°)
èªªæ˜ï¼špalbociclib ç‚ºCDK4/6æŠ‘åˆ¶åŠ‘ï¼Œå¸¸èˆ‡aromatase inhibitorä½µç”¨ï¼Œç”¨æ–¼ERâºã€HER2â» è½‰ç§»æ€§ä¹³ç™Œæ²»ç™‚ã€‚
???

##### 114-2(77) +
```Question
Finasterideä¹‹ä¸»è¦ä½œç”¨æ–¹å¼ç‚ºä½•ï¼Ÿ
```
(A) androgen antagonism
(B) Î±1-antagonism
(C) mitochondrial 11Î²-hydroxylase inhibition
(D) 5Î±-reductase inhibition
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šD
èªªæ˜ï¼šfinasteride ç‚º5Î±-reductaseæŠ‘åˆ¶åŠ‘ï¼Œé˜»æ­¢testosteroneè½‰æ›æˆæ›´å…·æ´»æ€§çš„DHTï¼Œç”¨æ–¼æ²»ç™‚å‰åˆ—è…ºè‚¥å¤§èˆ‡é›„æ€§ç¦¿ã€‚
???

##### 114-2(78)
```Question
ä¸‹åˆ—ä½•ç¨®VEGFRæŠ‘åˆ¶åŠ‘ï¼Œæœƒå°è‡´ç—…æ‚£çš®è†šèˆ‡é«”æ¶²è®Šé»ƒï¼Ÿ
```
(A)![[Pasted image 20250721114300.png]]
(B)![[Pasted image 20250721114217.png]]
(C)![[Pasted image 20250721114210.png]]
(D)![[Pasted image 20250721114159.png]]
?
ç­”æ¡ˆï¼šB
æˆ‘çš„å›ç­”ï¼šB (çŒœä¸­ï¼ŒSUN åƒæ˜¯é»ƒå¤ªé™½)
æ€è€ƒæ–¹å‘ï¼š
å¯è§€å¯Ÿé¸é …æ˜¯å¦ç‚º **rifampin-like çµæ§‹æˆ–å«æœ‰è‰²ç´ åŸºåœ˜**ï¼Œæœ‰äº›VEGFRæŠ‘åˆ¶åŠ‘å¦‚ **regorafenib æˆ– nintedanib** å¯èƒ½ç”¢ç”Ÿä»£è¬ç‰©ç´¯ç©ï¼Œå¼•èµ·çš®è†šèˆ‡é«”æ¶²è®Šè‰²ã€‚é€šå¸¸å«æœ‰é»ƒé…®æˆ–å…¶ä»–ç™¼è‰²åŸºåœ˜è€…è¼ƒæ˜“æœ‰æ­¤å‰¯ä½œç”¨ã€‚
???

##### 114-2(79) 
```Question
é€†è½‰éŒ„é…¶æŠ‘åˆ¶åŠ‘emtricitabineä¹‹çµæ§‹ï¼ˆå¦‚ä¸‹åœ–ï¼‰ï¼ŒRç‚ºä¸‹åˆ—ä½•ç¨®å–ä»£åŸºï¼Ÿ
```
![[Pasted image 20250721114134.png]]
(A) CH3
(B) C2H5
(C) F
(D) Cl
?
ç­”æ¡ˆï¼šC
æˆ‘çš„å›ç­”ï¼šA (æˆ‘æ˜¯ç™½ç™¡)
æ€è€ƒæ–¹å‘ï¼š
emtricitabine ç‚ºNRTIï¼ˆæ ¸è‹·é¡é€†è½‰éŒ„é…¶æŠ‘åˆ¶åŠ‘ï¼‰ï¼Œçµæ§‹é¡ä¼¼ lamivudineï¼Œä½†Rä½æ˜¯ **æ°Ÿï¼ˆFï¼‰**ï¼Œç‚ºå…¶å‘½åã€Œfluoro-cytidineã€ä¾†æºã€‚
???

##### 114-2(80) +
```Question
ä¸‹åˆ—ä½•ç¨®æŠ—çœŸèŒè—¥çµæ§‹ä¸­å¸¶æœ‰ç¡¼åŸå­ï¼Œä¸”å…·æœ‰è‰¯å¥½çš„ç°æŒ‡ç”²æ²»ç™‚æ•ˆæœï¼Ÿ
```
(A) butenafine
(B) butoconazole
(C) amorolfine
(D) tavaborole
?
ç­”æ¡ˆï¼šD
æˆ‘çš„å›ç­”ï¼šD
èªªæ˜ï¼štavaborole ç‚ºå«ç¡¼åŸå­çš„æŠ—çœŸèŒåŠ‘ï¼Œå¯æŠ‘åˆ¶çœŸèŒtRNAåˆæˆï¼Œå°ˆé–€ç”¨æ–¼ç°æŒ‡ç”²æ²»ç™‚ï¼Œçµæ§‹ä¸­å«æœ‰boronç’°ã€‚
???

```dataviewjs
let file = app.workspace.getActiveFile();
if (!file) {
  dv.paragraph("âš ï¸ ç„¡æ³•å–å¾—ç›®å‰ç­†è¨˜æª”æ¡ˆã€‚è«‹åœ¨æœ‰æ•ˆç­†è¨˜ä¸­ä½¿ç”¨æ­¤å€å¡Šã€‚");
  return;
}

let text = await app.vault.read(file);
let lines = text.split("\n");

let results = [];
let current = null;

for (let line of lines) {
  let titleMatch = line.match(/^#####\s*\d+-\d+\((\d+)\)/);
  if (titleMatch) {
    if (current) results.push(current);
    current = { num: Number(titleMatch[1]), ans: null, mine: null, mineRaw: "" };
    continue;
  }

  if (!current) continue;

  let ansMatch = line.match(/^ç­”æ¡ˆï¼š([A-D])/);
  if (ansMatch) {
    current.ans = ansMatch[1];
    continue;
  }

  if (line.startsWith("æˆ‘çš„å›ç­”ï¼š")) {
    current.mineRaw = line.replace("æˆ‘çš„å›ç­”ï¼š", "").trim(); // ä¿ç•™æ•´æ®µ
    let directMatch = current.mineRaw.match(/([A-D])/);       // æŠ“å‡ºç¬¬ä¸€å€‹ Aâ€“D
    if (directMatch) {
      current.mine = directMatch[1];
    }
    continue;
  }
}

if (current) results.push(current); // âœ… æ­£ç¢ºä½ç½®ï¼šfor è¿´åœˆå¤–

// === è©•åˆ† ===
let score = 0;
let wrong = [];

for (let q of results) {
  if (q.ans && q.mine && q.ans === q.mine) {
    score += 1.25;
  } else {
    wrong.push(q.num);
  }
}

// === è¼¸å‡º ===
dv.paragraph(`ğŸ¯ **ç¸½åˆ†ï¼š${score.toFixed(2)} / ${(results.length * 1.25).toFixed(2)}**`);
if (wrong.length > 0) {
  dv.paragraph("âŒ ç­”éŒ¯æˆ–æœªå¡«çš„é¡Œè™Ÿï¼š" + wrong.join(", "));
} else {
  dv.paragraph("âœ… å…¨éƒ¨ç­”å°ï¼");
}

dv.table(["é¡Œè™Ÿ", "æ¨™æº–ç­”æ¡ˆ", "æˆ‘çš„ä½œç­”", "åŸå§‹è¼¸å…¥"],
  results.map(q => [
    q.num,
    q.ans ?? "â“",
    q.mine ?? "â“" + (q.mine === null ? "ï¼ˆæœªä½œç­”ï¼‰" : ""),
    q.mineRaw || "ï¼ˆç„¡å…§å®¹ï¼‰"
  ])
);

```